CTNM

Contineum Therapeutics (CTNM)

About Contineum Therapeutics (CTNM)

Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company was founded by Daniel S. Lorrain on May 9, 2017 and is headquartered in San Diego, CA.

Details

Daily high

$11.77

Daily low

$11.50

Price at open

$11.52

52 Week High

$15.25

52 Week Low

$3.35

Market cap

341.8M

Dividend yield

0.00%

Volume

257,517

Avg. volume

273,962

P/E ratio

-5.13

Contineum Therapeutics News